Nature Reviews Drug Discovery, Published online: 10 August 2026; doi:10.1038/d41573-026-00135-0 As Takeda’s oveporexton (Orzeyful) becomes a first-in-class treatment for narcolepsy type 1, industry eyes broader indications for orexin receptor agonists.